

REGENERON

Regeneron Announces Presentation at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference

August 5, 2010

TARRYTOWN, N.Y., Aug 05, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference on Friday, August 13, 2010. The presentation is scheduled for 11:20 a.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through August 27, 2010.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Contact Information:

Michael Aberman, M.D.

Investor Relations

914.345.7799

michael.aberman@regeneron.com

Peter Dworkin

Corporate Communications

914.345.7800

peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved